UP!

EARS $3.05

EARS target price
3.04
0
0

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2018 2021-03-31 0.00 0.00
Q3 2018 2018-11-15 -2.80 -2.80

Ratings

2016-06-15 Reiterated Rating Leerink Swann Buy $12.00
2016-06-10 Reiterated Rating Jefferies Group Buy
2016-05-12 Reiterated Rating Leerink Swann Buy
2016-03-15 Lower Price Target Jefferies Group Buy $12.00 to $8.00
2016-01-06 Reiterated Rating Leerink Swann Outperform $12.00
2015-10-06 Reiterated Rating Leerink Swann Outperform
2015-10-01 Reiterated Rating Needham & Company LLC Buy $11.00
2015-06-02 Reiterated Rating Needham & Company LLC Buy $11.00
2015-05-26 Reiterated Rating Leerink Swann Outperform $12.00 to $10.00
2014-09-09 Initiated Needham Buy $11
2014-09-09 Initiated Coverage Needham & Company LLC Buy $11.00
2014-09-02 Initiated Coverage Leerink Swann Outperform $10.00
2014-09-02 Initiated Coverage JMP Securities Outperform $12.00
2014-09-02 Initiated Coverage Jefferies Group Buy $12.00
2016-06-15 Reiterated Rating Leerink Swann Buy $12.00
2016-06-10 Reiterated Rating Jefferies Group Buy
2016-05-12 Reiterated Rating Leerink Swann Buy
2016-03-15 Lower Price Target Jefferies Group Buy $12.00 to $8.00
2016-01-06 Reiterated Rating Leerink Swann Outperform $12.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In EARS 4 funds of 2213 total. Show all

Fund name Ticker shares
Sofinnova Management VIII, L.L.C. 7.82M
Adamant Biomedical Investments AG 2.17M
CLIFTON PARK CAPITAL MANAGEMENT, LLC 1.55M
KCG Holdings, Inc. 0.14M

Major Shareholders

Name Relationship Total Shares Holding stocks